514 related articles for article (PubMed ID: 32436027)
1. Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.
Canale ML; Camerini A; Casolo G; Lilli A; Bisceglia I; Parrini I; Lestuzzi C; Del Meglio J; Puccetti C; Camerini L; Amoroso D; Maurea N
Adv Ther; 2020 Jul; 37(7):3178-3184. PubMed ID: 32436027
[TBL] [Abstract][Full Text] [Related]
2. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
[TBL] [Abstract][Full Text] [Related]
3. Real-world data on patients with metastatic non-small-cell lung cancer treated with checkpoint inhibitors in an Italian Teaching Hospital in 2015-2018.
Veraldi M; Esposito S; Naturale MD; Oradei M; Cosco D; Francesco AE; Cicchetti A; Bidino RD
J Oncol Pharm Pract; 2021 Jun; 27(4):877-886. PubMed ID: 32686615
[TBL] [Abstract][Full Text] [Related]
4. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study.
Miura K; Sano Y; Niho S; Kawasumi K; Mochizuki N; Yoh K; Matsumoto S; Zenke Y; Ikeda T; Nosaki K; Kirita K; Udagawa H; Goto K; Kawasaki T; Hanada K
Thorac Cancer; 2021 Jul; 12(13):1983-1994. PubMed ID: 33990133
[TBL] [Abstract][Full Text] [Related]
5. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
6. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
[TBL] [Abstract][Full Text] [Related]
7. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
8. Reduction of pericardial effusion in advanced non-small cell lung cancer patients with KRAS, TP53, and MET mutation treated with nivolumab.
Cai Z; Yao Y
J Int Med Res; 2020 Aug; 48(8):300060520937490. PubMed ID: 32780611
[TBL] [Abstract][Full Text] [Related]
9. Pericardial effusion due to pembrolizumab-induced immunotoxicity: A case report and literature review.
Atallah-Yunes SA; Kadado AJ; Soe MH
Curr Probl Cancer; 2019 Oct; 43(5):504-510. PubMed ID: 30685067
[TBL] [Abstract][Full Text] [Related]
10. Pericardial effusion under nivolumab: case-reports and review of the literature.
Saade A; Mansuet-Lupo A; Arrondeau J; Thibault C; Mirabel M; Goldwasser F; Oudard S; Weiss L
J Immunother Cancer; 2019 Oct; 7(1):266. PubMed ID: 31627742
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
Hsu JC; Lin JY; Hsu MY; Lin PC
PLoS One; 2018; 13(8):e0202725. PubMed ID: 30142174
[TBL] [Abstract][Full Text] [Related]
12. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
13. Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
Ono K; Ono H; Toi Y; Sugisaka J; Aso M; Saito R; Kawana S; Aiba T; Odaka T; Matsuda S; Saito S; Narumi A; Ogasawara T; Shimizu H; Domeki Y; Terayama K; Kawashima Y; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
Cancer Med; 2021 Jul; 10(14):4796-4804. PubMed ID: 34121358
[TBL] [Abstract][Full Text] [Related]
14. Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab.
Pantano F; Russano M; Berruti A; Mansueto G; Migliorino MR; Adamo V; Aprile G; Gelibter A; Ficorella C; Falcone A; Russo A; Aieta M; Maio M; Martelli O; Barni S; Napolitano A; Roca E; Quadrini S; Iacono D; Russo A; Calvetti L; Occhipinti MA; Cortellini A; Vasile E; Passiglia F; Imperatori M; Calabrò L; Di Giacomo AM; Petrelli F; Pasquini G; Franchina T; Venditti O; Intagliata S; Galvano A; Fioroni I; Vincenzi B; Tonini G; Santini D
Expert Opin Biol Ther; 2020 Mar; 20(3):319-326. PubMed ID: 32011207
[No Abstract] [Full Text] [Related]
15. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.
Fujita K; Kim YH; Kanai O; Yoshida H; Mio T; Hirai T
Respir Med; 2019 Jan; 146():66-70. PubMed ID: 30665520
[TBL] [Abstract][Full Text] [Related]
16. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
17. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Buti S; Bersanelli M; Perrone F; Bracarda S; Di Maio M; Giusti R; Nigro O; Cortinovis DL; Aerts JGJV; Guaitoli G; Barbieri F; Ferrara MG; Bria E; Grossi F; Bareggi C; Berardi R; Torniai M; Cantini L; Sforza V; Genova C; Chiari R; Rocco D; Della Gravara L; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Citarella F; Russano M; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Follador A; Bisonni R; Tuzi A; Minuti G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Olmetto E; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Addeo A; Friedlaender A; Cannita K; Porzio G; Ficorella C; Carmisciano L; Pinato DJ; Mazzaschi G; Tiseo M; Cortellini A
Eur J Cancer; 2021 Jun; 150():224-231. PubMed ID: 33934059
[TBL] [Abstract][Full Text] [Related]
18. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.
Presotto EM; Rastrelli G; Desideri I; Scotti V; Gunnella S; Pimpinelli N; Vaccher E; Bearz A; Di Costanzo F; Bruggia M; Mini E; Maggi M; Peri A
J Endocrinol Invest; 2020 Mar; 43(3):337-345. PubMed ID: 31542865
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer.
Enomoto T; Tamiya A; Matsumoto K; Adachi Y; Azuma K; Inagaki Y; Kouno S; Taniguchi Y; Saijo N; Okishio K; Atagi S
Clin Transl Oncol; 2021 Mar; 23(3):582-590. PubMed ID: 32661824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
